Vanguard Information Technology Index Fund ETF (VGT) Stock Price Today
Aura AI Summary
Key Stats
- -MARKET_CAP
- -VOLUME
- -SECTOR
- $125.77FIFTY_TWO_WEEK_HIGH
- $83.51FIFTY_TWO_WEEK_LOW
- -TYPICAL_HOLD_TIME
- -ENTERPRISE_VALUE
- -DIVIDEND_YIELD
- -TRADING_ACTIVITY
Track Vanguard Information Technology Index Fund ETF (VGT) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Vanguard Information Technology Index Fund ETF has traded between a low of $83.51 and a high of $125.77, highlighting its annual price range. Buy and sell Vanguard Information Technology Index Fund ETF shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Vanguard Information Technology Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Most Recent News
Global infant heart monitor market to reach $7.93B by 2035 with 10.85% CAGR, driven by tech advances and home care demand
The global infant heart monitor market, valued at $2.83 billion in 2025, is projected to grow to $7.93 billion by 2035 at a CAGR of 10.85%. Growth is fueled by advances in wearable and wireless monitoring technologies, increased adoption of home care...

Halper Sadeh LLC probes fairness of major company sales for shareholders' benefit.
Halper Sadeh LLC is investigating whether shareholders of Arcosa, Bio-Techne, Iridium Communications, and LCI Industries are receiving fair deals in their companies' recent sales. The law firm suspects insiders may gain financial benefits not availab...

Europe approves TEPKINLY combo for relapsed follicular lymphoma, offering a chemo-free treatment option.
The European Commission has approved TEPKINLY (epcoritamab) combined with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma in adults. This marks the first bispecific antibody-based therapy authorized in Europe for se...
